NO920051L - Farmasoeytisk sammensetning for slanking - Google Patents

Farmasoeytisk sammensetning for slanking

Info

Publication number
NO920051L
NO920051L NO92920051A NO920051A NO920051L NO 920051 L NO920051 L NO 920051L NO 92920051 A NO92920051 A NO 92920051A NO 920051 A NO920051 A NO 920051A NO 920051 L NO920051 L NO 920051L
Authority
NO
Norway
Prior art keywords
slimming
pharmaceutical composition
ephedrine
human
reducing
Prior art date
Application number
NO92920051A
Other languages
English (en)
Other versions
NO920051D0 (no
Inventor
Arne Astrup
Original Assignee
Dak Lab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dak Lab As filed Critical Dak Lab As
Publication of NO920051D0 publication Critical patent/NO920051D0/no
Publication of NO920051L publication Critical patent/NO920051L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En farmasøytisk sammensetning for behandling av overvekt og fettsyke eller komplikasjoner derav, idet sammensetningen omfatter en kombinasjon av en adrenerg 6 agonist og et xantin, for eksempel en kombinasjon av efedrin og kaffein, i et vektforhold fra omtrent 1:8 til omtrent 1:24, beregnet (når e agonlsten ikke er L-efedrin) på den isotermogene mengden av L-efedrin og (når xantin ikke er kaffein) på den isotermogene mengden av kaffein for å oppnå en supra-addltiv termogen virkning i kroppen etter oral, rektal, nasal eller parenteral administrasjon, er beskrevet. Sammensetningen kan videre'bli anvendt i et husdyr for å forbedre kroppens innhold av kjått på bekostning av kroppens innhold av fett.
NO92920051A 1989-07-07 1992-01-03 Farmasoeytisk sammensetning for slanking NO920051L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK339289A DK339289D0 (da) 1989-07-07 1989-07-07 Farmaceutisk praeparat
PCT/DK1990/000106 WO1991000730A1 (en) 1989-07-07 1990-04-20 A slimming pharmaceutical composition

Publications (2)

Publication Number Publication Date
NO920051D0 NO920051D0 (no) 1992-01-03
NO920051L true NO920051L (no) 1992-01-31

Family

ID=8122369

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92920051A NO920051L (no) 1989-07-07 1992-01-03 Farmasoeytisk sammensetning for slanking

Country Status (19)

Country Link
US (1) US5422352A (no)
EP (1) EP0480934B1 (no)
JP (1) JP2584899B2 (no)
KR (1) KR0159045B1 (no)
AT (1) ATE107858T1 (no)
AU (1) AU638992B2 (no)
CA (1) CA2063598C (no)
DE (1) DE69010336T2 (no)
DK (2) DK339289D0 (no)
ES (1) ES2055911T3 (no)
FI (1) FI920026A0 (no)
HK (1) HK1001821A1 (no)
HU (1) HU220071B (no)
LT (1) LT3536B (no)
LV (1) LV10192B (no)
NO (1) NO920051L (no)
RU (1) RU2109511C1 (no)
UA (1) UA27779C2 (no)
WO (1) WO1991000730A1 (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5865869A (en) * 1991-08-02 1999-02-02 Ecologel Usa, Inc. Solution for plant root watering
AU4659793A (en) * 1992-06-30 1994-01-24 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Anorectic epinephrine derivatives
AU682156B2 (en) * 1992-10-15 1997-09-25 Dana-Farber Cancer Institute, Inc. Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-alpha function
ES2094687B1 (es) * 1994-08-02 1997-12-16 S A L V A T Lab Sa Combinacion farmaceutica contra la obesidad o el sobrepeso.
FR2746644A1 (fr) * 1996-03-18 1997-10-03 Firion Jackie Produit parapharmaceutique moderateur d'appetit
US6224873B1 (en) 1996-09-30 2001-05-01 Zhishin, Llc Regulation of appetite, body weight and athletic function with materials derived from citrus varieties
ATE453385T1 (de) * 1996-09-30 2010-01-15 Dennis Jones Regulation von körpergewicht durch materialien basierend auf zitrusvariationen
ES2259806T5 (es) 1996-12-23 2009-05-01 S.L.A. Pharma Ag Composicion farmaceutica para tratar la incontinencia fecal.
US5985282A (en) * 1997-01-22 1999-11-16 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
US5798101A (en) * 1997-01-22 1998-08-25 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
US6162455A (en) * 1997-01-22 2000-12-19 American Cyanamid Company Method for increasing lean meat, improving the lean meat to fat ratio and improving amino acid utilization in warm-blooded animals
HUP9700654A2 (hu) * 1997-03-26 1999-09-28 Dezső Korbonits Teobromin tartalmú köhögéscsillapító készítmények
US6468519B1 (en) * 1997-09-10 2002-10-22 Rutgers, The State University Of New Jersey Polyanhydrides with biologically active degradation products
US7232830B2 (en) 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
CA2336004C (en) * 1998-06-26 2006-10-24 Elaine A. Delack Use of histamine h2 agonists for the treatment of multiple sclerosis
US6340482B1 (en) 2000-05-18 2002-01-22 Zhishin, Llc Methods for inducing weight loss in a human with materials derived from Citrus varieties
US6113949A (en) * 1998-10-27 2000-09-05 Prolab Nutrition, Inc. Weight control product and method of treating hyperlipidemia and increasing vigor with said product
US6475514B1 (en) * 1998-12-03 2002-11-05 Andrew Blitzer Athletic patch
US6576272B1 (en) * 1999-03-05 2003-06-10 Twin Laboratories Incorporated Dietary supplement and method of using same
AU6221500A (en) * 1999-07-20 2001-02-05 Natrol, Inc. Weight control product comprising a synergistic mixture of guggul extract, phosphate salt and metabolic stimulant
EP1250131A2 (en) * 1999-08-23 2002-10-23 The Administrators Of The Tulane University Educational Fund Modulation of the blood-brain barrier transporter for leptin
US6723737B1 (en) * 1999-10-20 2004-04-20 Eliezer Rapaport Methods, pharmaceutical and therapeutic compostions for administering adenosine
US8178150B2 (en) 2000-02-22 2012-05-15 Suzanne Jaffe Stillman Water containing soluble fiber
US7892586B2 (en) 2001-02-22 2011-02-22 Suzanne Jaffe Stillman Water containing soluble fiber
US7115297B2 (en) * 2000-02-22 2006-10-03 Suzanne Jaffe Stillman Nutritionally fortified liquid composition with added value delivery systems/elements/additives
DE10011541A1 (de) * 2000-03-06 2001-09-20 Reimann Hartmut Verwendung einer Kombination aus Ephedrin und Coffein und/oder Theophyllin zur Vitalisierung von Knochenfischen, Wasserzusatz zur Vitalisierung von Knochenfischen
US6316499B1 (en) 2000-05-18 2001-11-13 Zhishin, Llc Methods for increasing the muscle mass of a human with materials derived from citrus varieties
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
US7048941B2 (en) * 2001-03-30 2006-05-23 New World Enterprizes, Inc. Chocolate composition as delivery system for nutrients and medications
US7041305B2 (en) * 2001-09-07 2006-05-09 Western Holdings, Llc Stable water in oil aminophylline emulsions
GB0130763D0 (en) 2001-12-21 2002-02-06 Norgine Res Ltd Treatment methods
WO2003088953A2 (en) * 2002-04-19 2003-10-30 N.V. Nutricia Multiphasic diet
US8142810B2 (en) * 2002-05-30 2012-03-27 The Procter & Gamble Company Dietary method for modulating glucose metabolism and associated conditions and increasing longevity
US20040077530A1 (en) * 2002-10-18 2004-04-22 Robert Portman Composition for reducing caloric intake
US20040224031A1 (en) * 2003-05-06 2004-11-11 Antonio Zorzano Olarte Combination of amines and vanadium (IV)/(V) compounds for the treatment and/or prevention of diabetes mellitus
EP1672988A4 (en) 2003-10-17 2008-02-20 Diet Formulations Ltd ADDITIONAL FOR WEIGHT REDUCTION
NZ547178A (en) * 2003-11-20 2008-06-30 Alteragon Pty Ltd Method of decreasing fat deposits and body weight in mammals and birdsusing the R-isomer of Salbutamol
CA2455248A1 (en) * 2004-01-29 2005-07-29 Alexander Zolotoy Oral administration of r-albuterol against obesity
US7524064B2 (en) * 2004-03-09 2009-04-28 Research Foundation Of The State University Of New York Apparatus and method for assessing retinal damage
US20060074057A1 (en) * 2004-10-04 2006-04-06 Eric Marchewitz Use of chenodeoxycholic acid for reducing adipose tissue
US20060134230A1 (en) * 2004-12-17 2006-06-22 Sal Abraham Weight loss composition and formulation
US20060204599A1 (en) * 2005-03-14 2006-09-14 Wheat Jared R Dietary supplement and method of using same
US20090214682A1 (en) * 2008-02-22 2009-08-27 Heuer Marvin A Composition and methods for weight loss in a subject
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
WO2012092056A1 (en) * 2010-12-29 2012-07-05 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue with targeted substance delivery
CN109043176A (zh) * 2012-10-08 2018-12-21 利维拉（澳大利亚）有限公司 包含莱克多巴胺和咖啡因的动物饲料补充剂
US9877434B2 (en) 2013-05-30 2018-01-30 Ecologel Solutions, Llc Granular compositions and methods for drought mitigation
NZ724579A (en) * 2014-03-26 2020-03-27 Rivalea Australia Pty Ltd Method for improving feed efficiency in ruminants
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
CN107404902A (zh) 2015-02-13 2017-11-28 马斯公司 宠物食物饲喂系统
US20180055848A1 (en) * 2015-04-14 2018-03-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Combination of Albuterol and Caffeine as Synergistic Treatment for Obesity or Sarcopenia
GB201522296D0 (en) 2015-12-17 2016-02-03 Mars Inc Food product to reduce body fat
US11090278B2 (en) 2019-05-16 2021-08-17 Nexus Pharmaceuticals, Inc. Compositions comprising ephedrine or an ephedrine salt and methods of making and using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2390164A1 (fr) * 1977-05-13 1978-12-08 Blanie Paul Association a action anti-asthmatique
FI772858A (fi) * 1977-06-03 1978-12-04 Pharmaceutical Export Promotio Avmagningsmedel och foerfarande foer framstaellning daerav
US4364922A (en) * 1980-10-14 1982-12-21 University Of Virginia Alumni Patents Foundation Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
US5011843A (en) * 1988-05-31 1991-04-30 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors

Also Published As

Publication number Publication date
CA2063598C (en) 1997-12-09
EP0480934B1 (en) 1994-06-29
WO1991000730A1 (en) 1991-01-24
HU220071B (hu) 2001-10-28
RU2109511C1 (ru) 1998-04-27
EP0480934A1 (en) 1992-04-22
FI920026A0 (fi) 1992-01-03
ATE107858T1 (de) 1994-07-15
LV10192A (lv) 1994-10-20
US5422352A (en) 1995-06-06
DE69010336D1 (de) 1994-08-04
LV10192B (en) 1995-06-20
KR0159045B1 (ko) 1998-12-01
JPH04507091A (ja) 1992-12-10
DE69010336T2 (de) 1994-11-03
NO920051D0 (no) 1992-01-03
LTIP702A (en) 1995-01-31
ES2055911T3 (es) 1994-09-01
LT3536B (en) 1995-11-27
AU638992B2 (en) 1993-07-15
DK0480934T3 (da) 1994-11-07
HU9200051D0 (en) 1992-06-29
CA2063598A1 (en) 1991-01-08
AU5630890A (en) 1991-02-06
JP2584899B2 (ja) 1997-02-26
DK339289D0 (da) 1989-07-07
HK1001821A1 (en) 1998-07-10
UA27779C2 (uk) 2000-10-16
HUT62798A (en) 1993-06-28

Similar Documents

Publication Publication Date Title
NO920051L (no) Farmasoeytisk sammensetning for slanking
YU47543B (sh) Postupak za dobijanje farmaceutskog preparata za stimulaciju granulocita
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
DE69738000D1 (de) Neue Arzneiformulierung enthaltend Budesonide
PT977564E (pt) Forscolina para promocao da massa corporal magra
DE68910159D1 (de) Dosierform für Verabreichung in der Humanmedizin.
SE9301290D0 (sv) Anvaendning av en somatostatinanalog
BE898749A (fr) Nouveau procede de preparation de formes galeniques utiles notamment en therapeutique, dietetique, cosmetique et diagnostic
DE3650358D1 (de) Diphosphonate enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Arthrosis.
EP0214254A1 (en) MELATONIN COMPOSITIONS AND USES THEREOF.
ES2176495T3 (es) Utilizacion de un antagonista de la bradiquinina, destinada a inducir y/o estimular el crecimiento de los cabellos y/o frenar su caida.
IL126175A (en) Pharmaceutical compositions containing endothelin antagonists and novel endothelin antagonists
BE885793A (fr) Sels d'acides 6,7-dihalo-3,4-dihydro-3-oxo-2-quinoxalinecarboxyliques et d'amines steriquement encombrees, leur preparation et leur utilisation therapeutique
BR9911237A (pt) Novo uso de um derivado de piridazinona
KR900007434A (ko) 시스타틴을 유효 성분으로하는 치료제
IT8026233A0 (it) Derivato della n-acetil-cisteina ad attivita' terapeutica, procedimento per la sua preparazione e relative composizioni farmaceutiche.
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
AR008155A1 (es) Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
GB2004183A (en) Compositions containing caffeine and ephedrine or their derivatives
ATE72397T1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
GB2019720A (en) S-adenosyl-L-homocysteine and salts thereof for use in therapy
RU94002713A (ru) Способ лечения детей с синдромом удлиненного интервала qт (романо-уорда)
RU96122371A (ru) Способ лечения эндогенных и послеоперационных увеитов
DE60217302D1 (de) Erhaltung von körpereigenen proteinen
FR2418226A1 (fr) Methoxy-2 alkylthio-5 benzamides et leur application en therapeutique